objeCtives: To estimate budget impact analysis (BIA) of belimumab plus standard of care (SoC) comparing the SoC alone in the treatment of patients suffering from systemic lupus erythematosus (SLE). Methods: BIA was conducted of the belimumab treatment plus SoC vs SoC alone. Costs of treatments in both groups contained following direct medical costs: costs of drugs and administration, costs of diagnostic laboratory and instrumental procedure, costs of inpatient and outpatient visits, costs of SLE complications and also adverse event costs. A five-year time horizon was used. All costs in both groups were estimated to their present value using a 5 % discount rate. Results: Costs of the course of belimumab therapy were 2,118,449 RUB/ 45,581 EUR for 5 years but the difference in the required budget funds between belimumab treatment groups and SoC alone treatment group amounted to 1,876,965 RUB/ 40,385 EUR for 5 years with a 5 % discount rate. The decrease of the difference in the required budget funds between these two groups was due to a lower so. Results: Our 1. hypothesis, that the children with normal weight move much, than their obese companions, not proven true (p= 0,778). It was the next supposition that less are truth with a subject for the students with normal weight they have difficulties, than for the obese students. According to the examination, the normal one and the obese child with a subject truth in the look of difficulty, we found a significant difference (p= 0,015). The third hypothesis, that, in the obese group taller the anxious children's proportion, than the did not grow fat in a group, not proven true. The overweight children (n= 46, medium= 109, 76) anxiety with a significantly bigger degree was not showed based on the scale the normal one tápláltsági state at students (n= 95, medium= 104, 56 dot, p= 0,515). ConClusions: The enrolled students showed no significant difference between the observed parameters of the overweight and sporting habits. objeCtives: To estimate the costs of drug supply for registered rare diseases (RD) patients in Russia in 2013. Methods: The study included two steps: 1) the analysis of the current situation with financing of drugs for RD patients in Russia in 2013 and 2) estimating the unmet needs -necessary weighted average costs (nWAC) for a pathogenetic pharmacotherapy of registered patients with RD in the same year. Number of registered patients with 24 RD listed in the Government Regulation of Russian Federation № 403 from April 26, 2012 was estimated for the studied year. Number of registered patients and actual financing has been received from the database of regional public health services. The nWAC for expensive pathogenetic pharmacotherapy of patients with 24 RD were calculated on the basis of standards of therapy and experts' survey results. The current situation with financing of RD drugs in Russia in 2013 was compared with unmet needs (nWAC). Results: 4.4 billion rubles ($125.7 million) were spent from regional budgets in Russia for 11,173 patients (0.008% from all population of Russia) with 24 RD in 2013. The largest patient group with 3,460 patients was a classic phenylketonuria group. The prognostic annual nWAC for pharmacotherapy of the most expensive patient with type VI mucopolysaccharidosis were 40.9 million rubles ($1.2 million) per child and 71.5 million rubles ($2.0 million) per adult. The nWAC for pharmacotherapy of registered patients with 24 RD in 2013 were 15.7 billion rubles ($448.6 million). The annual nWAC for pharmacotherapy of the most expensive disease (idiopathic thrombocytopenic purpura (Evans syndrome) was estimated as 2.9 billion rubles ($82.8 million) per group of 2,700 patients. ConClusions: The state financing of pharmacotherapy for patients with 24 RD in Russia should be increased approximately in 3.5 times to fulfill the unmet needs. objeCtives: Ultra-rare disorders (URDs) have been defined by a prevalence of less than 1 per 50,000 persons. On a per patient basis, the annual acquisition costs of drugs for URDs can be very high, and there have been concerns that expenditures for these products might escalate in the future. The goal of this study was therefore to provide a budget impact analysis (BIA) of drugs for ultra-rare non-oncological diseases in Europe. Methods: The BIA had a time horizon of 10 years (from 2012 to 2021) and adopted the perspective of all European payers in combination. The was calculated. Considering a switch to aztreonam lysine, the reduction of exacerbation was estimated in order to maintain the overall treatment cost. For the base case, ex-factory prices were considered; for sensitivity analysis, discounts ranged from 15 to 50%. Results: Switching to aztreonam lysine would not increase overall treatment costs in 8/12 options; even maintaining current exacerbation episodes could lead to SNS savings. In the remaining options, the required reduction of exacerbations varies depending on the patient's current situation, ranging from 110% (one episode/ year) to 18% (six episodes/year). In the sensitivity analysis, there are 3 options in which switching to aztreonam lysine would not imply higher treatment costs. For the remaining alternatives, the required reduction of exacerbations does not change significantly from the base case: from 116% (one episode/year) to 19% (six episodes/ year). ConClusions: In CF patients with chronic pulmonary infection by PA, hospitalizations costs due to exacerbations have a greater economic impact than drug treatment costs. Using aztreonam lysine, instead of other treatments, would not imply a budget impact in a wide range of patient profiles if exacerbation episodes can be reduced. As the number of current exacerbations increases, a lesser reduction of these events is required by a switch to aztreonam lysine to avoid incremental treatment costs.
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PSY30
ImPact of generIc SuBStItutIon on the PreScrIBIng of meProBamatecontaInIng comBInatIon analgeSIcS In South afrIca
Truter I. Nelson Mandela Metropolitan University, Port Elizabeth, South Africa objeCtives: Meprobamate is a constituent of various combination analgesics in South Africa. Due to its abuse potential, the scheduling status of meprobamate is currently under review with the possibility of introducing stricter controls on its availability. The primary aim was to determine the impact of generic substitution on meprobamate-containing combination analgesic prescribing. Methods: A retrospective, cross-sectional drug utilisation study was conducted on prescription data of a medical insurance scheme administrator in South Africa for 2011. Results: A total of 97 491 analgesics were dispensed to 31 854 patients during the year. Within ATC category N02B, 62.10% of prescriptions were for analgesic combinations, of which 20 326 prescriptions were for meprobamate-containing analgesics at a cost of R282 930. A total of 10 404 patients received meprobamate-containing analgesics. Overall, 20.85% of all analgesics contained meprobamate. Patients who received meprobamate-containing analgesics were slightly older (39.52 years) compared to patients who received analgesics in general (33.61 years). Mandatory generic substitution exists in South Africa, unless otherwise indicated by the prescriber or if the patient refuses. Twenty-two trade names of meprobamate-containing analgesics were dispensed, of which 17 (the originator plus 16 branded generics) contained exactly the same dosages of active ingredients (320 mg paracetamol, 8 mg codeine phosphate, 32 mg caffeine and 150 mg meprobamate). In previous studies, the originator product was the most often prescribed, yet in this study the originator product only constituted 3.72% of products prescribed (average cost: R30.42) compared to 70.63% for the most popular branded generic (average cost: R11.65). ConClusions: The price difference between generic equivalents and the originator product, together with mandatory generic substitution, were responsible for the change in prescribing patterns.
PSY31 the economIc Burden of treatIng thalaSSemIa In greece
objeCtives: The objective was to estimate the economic burden of B-thalassemia and to compare the cost of alternative iron chelation strategies in patients with transfusion (TDT) and non-transfusion dependent thalassemias (NTDT) in Greece. Methods: A multicenter, non interventional, retrospective, observational, phase IV study was conducted in the 3 out of 8 thalassemia units in Attica. Patients' data and resource use, including medication and related consumables, blood transfusions, lab tests, diagnostic examinations and hospital visits were recorded from January 2009 to December 2011, and classified per diagnosis and iron chelation treatment strategies. Greek NHS perspective was considered. Results: 331 thalassemic patients were recorded whereas the majority (87.6%) was diagnosed with Betathalassemia major, 31% were treated with deferasirox (DFX), 23% with deferoxamine and deferiprone, (DFO+DFP), 9.7% with deferiprone (DFP) and 5.1% with DFO. Patient mean annual cost per patient was € 32,064, including all treatment strategies, for the period 2009 -2011 , ranging from € 30,997 in 2009 to € 32,564 in 2011 , blood transfusions (38.1%) and consumables (14.9%) were the most important cost drivers. Mean cost per patient treated with DFX was estimated at € 35,928, with DFO+DFP at € 34,035, with DFO at € 31,637 and with DFP at € 17,208 for the same period. DFX significantly reduced (p< 0.001) the number of blood transfusions in relation to DFO+DFP with 19 and 25 transfusions per year, respectively. Similarly, DFX significantly reduced the volume of blood transfusions (p< 0.001) in relation to DFO with 9,693ml and 10.312ml per year, respectively. ConClusions: Rational health care decision making process should be based on the holistic perspective of analytical resource use and disease management data rather than focusing on the price per product per se. Especially in Greece, a country where Beta-thalassemia incidence in general population is ~8 %, the consideration of all cost components should be taken into account in health resource allocation. objeCtives: The aim of the study was to determine public expenditure on medicines for rare diseases from the public health sector in the Czech Republic (CZ). Methods: We identified orphan medicinal products (OMPs) registered by the European Medicines Agency (EMA) until December 2013 in the public database of EMA. In the base-case scenario, medicinal products available in the CZ were considered OMPs only within the interval of marketing authorisation date and December 2013 or OMP designation withdrawal date or date of withdrawal of use. Reports on consumption and real expenditures of these OMPs came from all health insurance companies in the CZ. Exchange rate of 25.4 CZK = 1 EUR was used. Results: Overall, 86 OMPs were authorised within the European Union (EU) between 2008 and 2013. Of these, 50 OMPs (58.0%) were covered from the Czech public health insurance at some point within this period. The number of registered OMPs increased from 54 in 2008 to 84 in 2013, while the number of covered OMPs doubled from 24 to 41, respectively. The annual public expenditure on OMPs rose simultaneously from 43 to 72 million EUR, while the total expenditure on drugs increased from 1.7 to 2.0 billion EUR. The OMP share of total pharmaceutical sales grew steadily from 2.5% in 2008, reaching 3.4% in 2011 and plateaued at 3.6% in 2013. Twenty-one oncological OMPs (51.2%) generated up to 72.6% of the overall orphan costs in 2013. ConClusions: Compared to other EU countries, the Czech public expenditure on OMPs of 3.6% of all drugs seems to be relatively high. The major part of OMP costs is in oncological diagnoses. One of the limitations is the exclusion of designated OMPs not authorised by EMA since these OMPs still might be present on the market and reimbursed. This aspect needs further investigation. objeCtives: The objective of this analysis was to estimate and compare the annual cost per patient of the administration of capsaicin 8% patch, Qutenza ® , in Primary and Secondary Care for the treatment of adult patients with peripheral neuropathic pain (PNP). The annual cost per patient treated with Qutenza ® was also compared with Pregabalin and Lidocaine in Primary Care. Methods: The costs per patient for each treatment were estimated by analysing the health care resources associated with the use of pregabalin, lidocaine and Qutenza ® for the treatment of PNP from the perspective of the Spanish National Health System. Healthcare resources associated with the three pharmacological treatments considered were administration time and health care personnel, complementary non-pharmacological treatment, hospitalisation, adverse effects and concomitant medication, EUR 2013. Total costs per patient were estimated and compared both including and excluding concomitant medication to estimate the effect on the treatment costs. Results: The annual treatment cost per patient when Qutenza ® is administrated in the hospital was estimated at € 5,387.32 and € 5,259.19 when administered in Primary Care. Qutenza ® applied in Primary Care for the treatment of PNP showed annual savings of € 128.14 per patient compared with the administration of Qutenza ® in Secondary Care. Overall, the annual treatment costs per patient with pregabalin or lidocaine were estimated at € 14,074.14 and € 5,998.09, respectively, resulting in savings of € 8,814.95 and € 738.9 respectively when compared with the annual cost per patient when treated with Qutenza ® in Primary Care. ConClusions: The introduction of Qutenza ® into Primary Care for the treatment of PNP is expected to result in annual savings due to lower administration costs associated with the use of Qutenza ® and savings in health care personnel in Primary Care. Qutenza ® also showed to be the less expensive option in comparison with pregabalin or lidocaine, independent of the area of administration. Fe, Valencia, Spain, 2 Hospital La Princesa, Madrid, Spain, 3 Hospital Universitario La Paz, Madrid, Spain, 4 Hospital Universitari Vall d'Hebron, Barcelona, Spain, 5 Pharmacoeconomics & Outcomes Research Iberia, Madrid, Spain objeCtives: Estimate, from the Spanish National Healthcare System (SNS) perspective, the required reduction of exacerbation episodes in different patient profiles to maintain constant the overall treatment cost if a chronic treatment with inhaled antibiotics is switched to aztreonam lysine in patients with cystic fibrosis (CF) and chronic pulmonary infection by Pseudomonas aeruginosa (PA). Methods: A cost comparison model was developed considering two criteria to define patient profiles: current drug treatment (12 options linked to tobramycin and/or colistimethate sodium) and current exacerbation episodes (1-6/year). For each patient profile the overall treatment cost
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